The involvement of adenosine receptors in the effect of dizocilpine on mice in the elevated plus-maze

European Neuropsychopharmacology

Volumn 7, Issue 4, 1997, Pages 267-273

  Fraser, C M ^a   Fisher, A ^a   Cooke, M J ^a   Thompson, I D ^a   Stone, T W ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Adenosine; Anxiety; Dizocilpine; Glutamate; MK 801; N methyl D aspartate; NMDA; Plus maze; Purines

Indexed keywords

ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2 RECEPTOR; ADENOSINE RECEPTOR; DIZOCILPINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EXPLORATORY BEHAVIOR; LOCOMOTION; MALE; MAZE TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; TRANQUILIZING ACTIVITY;

ADENOSINE; ANIMALS; DIZOCILPINE MALEATE; DRUG INTERACTIONS; EXCITATORY AMINO ACID ANTAGONISTS; MALE; MICE; MOTOR ACTIVITY; RECEPTORS, N-METHYL-D-ASPARTATE; RECEPTORS, PURINERGIC P1; XANTHINES;

EID: 0030731553     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(97)00032-1     Document Type: Article

References (31)

1. Barraco, R.A., 1991. Behavioural actions of adenosine and related substances, in: J.W. Phillis (Ed.), Adenosine and Adenine Nucleotides, CRC Press, Boca Raton, pp. 339-366.
2. Burke S.P., Nadler J.V. Regulation of glutamate and aspartate release from slices of the hippocampal CA1 area: effects of adenosine and baclofen. J. Neurochem. 51:1988;1541-1551.
3. Coffin V.L., Spealman R.D. Modulation of the behavioural effects of clordiazepoxide by methylxanthines and analogues of adenosine in squirrel monkeys. J. Pharmacol. Exp. Ther. 235:1985;724-728.
4. Commissaris R.L., McCloskey T.C., Damian G.M., Brown B.D., Barraco R.A., Altman H.J. Antagonism of the anti-conflict effects of phenobarbital, but not diazepam, by the A-1 adenosine agonist l-PIA. Psychopharmacology. 102:1990;283-290.
5. Corbett R., Dunn R.W. Effect of 5,7-dichlorokynurenic acid on conflict, social interaction and plus-maze behaviours. Neuropharmacology. 32:1993;461-466.
6. Corradetti R., Le Conte G., Moroni F., Passani B., Pepeu G. Adenosine decreases aspartate and glutamate release from rat hippocampal slices. Europ. J. Pharmacol. 104:1984;19-26.
7. Correiadesa P., Sebastiao A.M., Ribeiro J.A. Inhibitory and excitatory effects of adenosine receptor agonists on evoked transmitter release from phrenic nerve endings of the rat. Brit. J. Pharmacol. 103:1991;1614-1620.
8. Fastbom J., Fredholm B.B. Inhibition of (3H) glutamate release from rat hippocampal slices by L-PIA. Acta Physiol. Scand. 125:1985;121-123.
9. Feuerstein T.J., Hertting G., Jackisch R. Modulation of hippocampal serotonin release by endogenous adenosine. Europ. J. Pharmacol. 107:1985;233-242.
10. Handley S.L., McBlane J.W. An assessment of the elevated X-maze for studying anxiety and anxiety-modulating drugs. J. Pharmacol. Toxicol. Methods. 29:1993;129-138.
11. Haraguchi H., Kuribara H. Behavioural effects of adenosine agonists: evaluation by punishment, discrete shuttle avoidance and activity tests in mice. Japan J. Pharmacol. 55:1991;303-310.
12. Jain N., Kemp N., Adeyemo O., Buchanan P., Stone T.W. Anxiolytic activity of adenosine receptor activation in mice. Brit. J. Pharmacol. 116:1995;2127-2133.
13. Kehne J.H., McCloskey T.C., Baron B.M., Chi E.M., Harrison B.L., Whitten J.P., Palfreyman M.G. NMDA receptors complex antagonists have potential anxiolytic effects as measured with separation induced ultrasonic vocalisations. Europ. J. Pharmacol. 193:1991;283-292.
14. Kirkpatrick K.A., Richardson P.J. Adenosine receptor mediated modulation of acetylcholine release from rat striatal synaptosomes. Brit. J. Pharmacol. 110:1993;949-954.
15. Lister R.G. The use of a plus-maze to measure anxiety in the mouse. Psychopharm. 92:1987;180-185.
16. MacGregor D.G., Miller W.J., Stone T.W. Mediation of the neuroprotective actions of R-PIA through a centrally located adenosine A1 receptor. Brit. J. Pharmacol. 110:1993;470-476.
17. Michaelis M.L., Michaelis E.K., Myers S.L. Adenosine modulation of synaptosomal dopamine release. Life Sci. 24:1979;2083-2092.
18. Pellow S., File S.E. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus maze: a novel test of anxiety in the rat. Pharmacol. Biochem. Behav. 24:1986;525-529.
19. Pellow S., Chopin P., File S.E., Briley M. Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Meth. 14:1985;149-167.
20. Plaznik A., Palejko W., Nazar M., Jessa M. Effects of antagonists at the NMDA receptor complex in two models of anxiety. Eur. Neuropsychopharmacol. 4:1994;503-512.
21. Rodgers, R.J. and Cole, J.C., 1994. The elevated plus-maze: pharmacology, methodology and ethology, in: S.J. Cooper, C.A. Hendrie (Eds.), Ethology and Psychopharmacology, Wiley, Chichester, pp. 9-44.
22. Rupniak N.M.J., Boyce S., Tye S., Cook G., Iversen S.D. Anxiolytic-like and antinociceptive effects of MK-801 accompanied by sedation and ataxia in primates. Pharmacol. Biochem. Behav. 44:1993;153-156.
23. Schingnitz G., Kufner-Muhl U., Ensinger H., Lehr E., Kuhn F.G. Selective A1-antagonists for treatment of cognitive deficits. Nucleosides and Nucleotides. 10(5):1991;1067-1076.
24. Sharma A.C., Kulkarni S.K. MK801 produces antianxiety effect in elevated plus-maze in mice. Drug Dev. Res. 22:1991;251-258.
25. Soderpalm A.K., Blomqvist O., Engel J.A., Soderpalm B. Characterisation of the anticonflict effect of MK-801, a non-competitive NMDA antagonist. Pharmacol. Toxicol. 76:1995;122-127.
26. Spignoli G., Pedata F., Pepeg G. A1 and A2 adenosine receptors modulate ACh release from brain slices. Eur. J. Pharm. 96:1984;341-342.
27. Stone, T.W. and Simmonds, H.A., 1991. Purines: Basic and clinical aspects, Kluwer Academic Press
28. Thompson S.C., Haas H.L., Gahwiler B.H. Comparison of the actions of adenosine at pre-and postsynaptic receptors in the rat hippocampus in vitro. J.Physiol. 451:1992;347-363.
29. Trussel L.D., Jackson M.B. Adenosine activated K+ conductance in cultured striatal neurons. Proc. Natl. Acad. Sci. U.S.A. 82:1985;4857-4861.
30. Willetts J., Balster R.L., Leander J.D. The behavioural pharmacology of NMDA receptor antagonists. TIPS. 11:1990;423-428.
31. Zetterstrom T., Fillenz M. Adenosine agonists can both inhibit and enhance in vivo striatal dopamine release. Europ. J. Pharmacol. 180:1990;137-143.